Assistant Professor, School of Nutrition and Health Promotion, ASU
My research has been primarily focused on exploring the effects of a novel, high-intensity interval exercise paradigm on cardiovascular and metabolic physiology in severe chronic diseases such as congestive heart failure and cardiac toxicity in breast cancer survivors. I specifically utilize exercise training as a pleiotropic “drug” to modify the disease process and to understand the mechanisms of disease in individuals suffering from these conditions. Furthermore, I have also been involved in the development of a novel risk score (utilizing peak oxygen uptake) for predicting the risk of major adverse cardiovascular events in patients with end-stage renal disease undergoing renal transplantation.
Heart failure is a major worldwide health concern and is the leading cause of hospitalization among elderly Americans. Approximately 50% of those diagnosed with heart failure have heart failure with preserved ejection fraction (HFPEF). HFPEF presents a therapeutic dilemma because pharmacological strategies that are effective for the treatment of heart failure and reduced ejection fraction have failed to show benefit in HFPEF. Aerobic exercise is an emergent treatment modality that may help improve left ventricular diastolic function in these patients. My research focuses principally on the effects of exercise intensity on markers of diastolic dysfunction and vascular function in patients with heart failure and preserved ejection fraction.